中證監要求蜜雪冰城就曾申請A股上市等五個事項補充資料
據內媒報道,中證監上周要求蜜雪冰城補充說明此前申請A股上市,以及是否存在對在香港上市產大重大影響等五個事項,於本月蜜雪冰城向港交所(00388.HK)遞交上市申請。
證監會要求蜜雪冰城提交的補充資料包括,說明公司歷史沿革;說明子公司鄭州蜜雪冰城教育科技股份是否涉及《境內企業境外發行證券及上市管理試行辦法》第八條規定的禁止上市融資的情形、說明今次申請「全流通」股東所持股份是否有被質押、凍結或其他有爭議的情形以及是否依規定予以揭露;以及說明開
發、經營網站、App及小程式等產品的資料收集使用情況,以及上市前後個人資訊保護與資料安全的安排或措施等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.